Nudix hydrolase (NUDT15) mutations have similarly been implicated in leukopenia risk in European and Asian populations (31–34); a randomized trial (n = 118) demonstrated that adjusting dosing based on NUDT15 genotype significantly reduced leukopenia (35). This evidence concerns the gene NUDT15 and Decreased total leukocyte count.